Back Hepatitis C

Hepatitis C

AbbVie's Viekira "3D" Combo for Hepatitis C Wins FDA Approval

The U.S. Food and Drug Association this week approved AbbVie's Viekira Pak for people with genotype 1 chronic hepatitis C, including patients with compensated cirrhosis. The regimen -- formerly known as "3D" -- consists of the HCV protease inhibitor paritaprevir, a ritonavir booster, and the NS5A inhibitor ombitasvir in a once-daily coformulation, taken with the twice-daily non-nucleoside HCV polymerase inhibitor dasabuvir.

alt

AASLD 2014: ACH-3102 plus Sofosbuvir Cures All Hepatitis C Patients in Phase 2 Study

Achillion's second-generation HCV NS5A inhibitor ACH-3102 combined with sofosbuvir (Sovaldi) was well-tolerated and led to sustained virological response in all treatment-naive genotype 1 hepatitis C patients in the Phase 2 PROXY study, according to late-breaking findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. Another early study showed promising results for Achillion's nucleotide polymerase inhibitor ACH-3422.

alt

AASLD 2014: Sofosbuvir/ Ledipasvir Cures Most Previously Treated HCV Patients with Cirrhosis

Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of therapy with first-generation HCV protease inhibitors had a sustained virological response rate of 97% when retreated with sofosbuvir/ledipasvir (Harvoni) for 24 weeks, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Sofosbuvir/ledipasvir also worked worked well for people previously treated with other sofosbuvir-containing regimens.

alt

Cured Hepatitis C Patients May Have Same Life Expectancy as General Population

Chronic hepatitis C patients with advanced liver fibrosis or cirrhosis who achieve sustained virological response to treatment have a life expectancy matching that of the general population, according to findings from a retrospective study published in the November 12 Journal of the American Medical Association. Those who were not cured, however, had significantly reduced survival.

alt

AASLD 2014: Screening Baby Boomers for HCV More Effective than Risk-based Testing

Age cohort screening for hepatitis C virus (HCV) identified 4 times as many people as prevailing screening protocols and can be "feasibly implemented," according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston.

alt

AASLD 2014: 1 Million People with Hepatitis C in the U.S. Meet High Priority Criteria for Treatment

An estimated 813,000 people with diagnosed hepatitis C in the U.S. have undergone liver disease staging and meet the "highest" or "high" priority criteria for immediate treatment, according to an analysis presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. The number would be even higher if taking into account undiagnosed individuals and prisoners and others excluded from household surveys.

alt

AASLD 2014: AbbVie 3D Cures Recurrent HCV in Most Liver Transplant Recipients Without Cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston and published in the November 11 advance edition of the New England Journal of Medicine.

alt

AASLD 2014: Many Hepatitis C Patients with Cirrhosis or Advanced Fibrosis Face Liver Failure

Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within 5 years, and 23% and 11%, respectively, died, according to a study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston. These findings underscore the urgent need for treatment for such individuals.

alt

AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV

A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.

alt